Anemia of Inflammation
Anemia of Inflammation
复制标题
DOI：
10.1182/asheducation-2010.1.276
复制
发表时间：
2010-12-01
期刊：
影响因子：
--
通讯作者：
Roy, Cindy N.
中科院分区：
文献类型：
--
作者：
Roy, Cindy N.
由各种病因引起的炎症，包括感染、自身免疫性疾病、慢性疾病和衰老，可以促进贫血。炎症性贫血（AI）最常见的是正常红细胞和正常色素，通常是轻度的。全身铁处理、红细胞生成和红细胞寿命的特征性变化都有助于AI。首选治疗针对基础疾病。然而，当炎症性损伤是顽固性的，或者原因尚未被诊断出来时，AI的治疗选择有限。由于贫血是一种与各种慢性疾病状态的不良结局相关的共病，因此了解其发病机制并开发新的治疗工具仍应是优先事项。铁调素抗菌肽作为一种有效的铁利用率调节剂，近年来已成为关注的焦点。随着铁调素定量分析技术的改进，铁调素在各种疾病状态中的作用也被揭示出来。最近的见解有关的调节途径，修改hepcidin的表达已经确定了新的药物开发的目标。随着该领域在此类治疗方面的进展，分析标准化血红蛋白对疾病结果的影响将证实贫血是否是与炎性疾病相关的发病率和死亡率的可逆独立贡献者。
Inflammation arising from various etiologies, including infection, autoimmune disorders, chronic diseases, and aging, can promote anemia. The anemia of inflammation (AI) is most often normocytic and normochromic and is usually mild. Characteristic changes in systemic iron handling, erythrocyte production, and erythrocyte life span all contribute to AI. The preferred treatment is directed at the underlying disease. However, when the inflammatory insult is intractable, or the cause has not been diagnosed, there are limited options for treatment of AI. Because anemia is a comorbid condition that is associated with poor outcomes in various chronic disease states, understanding its pathogenesis and developing new tools for its treatment should remain a priority. Hepcidin antimicrobial peptide has taken center stage in recent years as a potent modulator of iron availability. As the technology for quantitative hepcidin analysis improves, hepcidin's role in various disease states is also being revealed. Recent insights concerning the regulatory pathways that modify hepcidin expression have identified novel targets for drug development. As the field advances with such therapeutics, the analysis of the impact of normalized hemoglobin on disease outcomes will confirm whether anemia is a reversible independent contributor to the morbidity and mortality associated with inflammatory diseases.